• B Havlickova and G H Weyandt.
• Global Clinical Development Dermatology, Bayer HealthCare, Berlin, Germany.
• Int. J. Clin. Pract. 2014 Nov 1; 68 (11): 138813991388-99.

AimTo conduct a systematic review of treatments for anal eczema (AE).MethodsWe conducted a Medline search for clinical trial data for the treatment of perianal diseases including AE, including papers not published in the English language. We assessed the study reports using the system recommended by the Oxford Centre for Evidence-based Medicine. No meta-analysis was attempted.ResultsThe evidence base for topical treatments used to treat AE is very poor: there are very few studies and many of those that exist are of poor quality. The best evidence was found for medications that are yet to be licensed for AE. Among products with existing licences for the treatment of eczema, our assessment found some evidence to support the continued use of mild-to-moderate corticosteroids first line in most patients.DiscussionFeatures of the perianal region, and the fact that it is almost always occluded, mean that not all medications recommended in the general treatment guidelines for eczema are appropriate for AE. However, there are no specific treatment guidelines for these patients. This may in part be because of the lack of high-quality evidence-based medicine in this therapy area. Many frequently prescribed medications were developed and licensed many years ago, in an era when clinical trial design was not expected to be as rigorous as it is today.ConclusionThis review highlights the need to conduct more high-quality clinical trials in patients with AE in order that specific guidelines for the management of this difficult proctological condition can be prepared.© 2014 The Authors. International Journal of Clinical Practice Published by John Wiley & Sons Ltd.

11 keywords...

hide…